MVA-BN (‎Modified Vaccinia Ankara – Bavarian Nordic)‎ smallpox and mpox vaccine: Interim guidance

Auteurs

Langues

Année de publication

2024

Type

Orientations

Catégories

Maladies

Organisations

Régions de l'OMS

Mpox-Policy

Cette ressource apparaît sur le Thème suivant:

Cette ressource est incluse dans le tableau suivant:

Titre	Auteur	Année	Type	Langue
Smallpox and mpox (orthopoxviruses): WHO position paper	World Health Organization (WHO)	2024	Guidance	Anglais, Français
Summary of WHO SAGE recommendations for mpox vaccines, including considerations for off-label use	World Health Organization (WHO)	2025	Presentation	Anglais
Off-label vaccine use: explanatory note for countries	World Health Organization (WHO)	2024	Guidance	Anglais
MVA-BN (‎Modified Vaccinia Ankara – Bavarian Nordic)‎ smallpox and mpox vaccine: Interim guidance	World Health Organization (WHO)	2024	Guidance	Anglais, Français
ETF statement on the use of Imvanex for the prevention of mpox in children below 12 years of age	European Medicines Agency	2024	Guidance	Anglais
Regulatory & Policy Considerations for Mpox Vaccines in African Countries	World Health Organization (WHO), European Medicines Agency, Bavarian Nordic	2025	Presentation	Anglais
LC16m8 (live-attenuated freeze-dried vaccinia) smallpox and mpox vaccine - Interim Guidance	World Health Organization (WHO)	2025	Guidance	Anglais, Français
Frequently Asked Questions (FAQ) on use of fractional dosing with intradermal administration of mpox MVA-BN vaccine in the context of vaccine supply-constrained outbreak response	World Health Organization (WHO)	2025	Guidance	Anglais

Ajouté le: 2025-01-15 06:09:23

Consultations: 2128

Orientations